Industry Newsoncologyclinical trialstango therapeuticspartnerships
Tango Therapeutics Posts Revenue Growth, Trials Underway
3.9
Tango Therapeutics reported a 52.15% week-on-week stock jump this week after Stifel reaffirmed a "buy" rating and as it begins clinical trials for vopimetostat in pancreatic cancer. The company said 2024 revenues rose 48.3% to $62.38 million and narrowed full-year net losses to $101.59 million, while fourth-quarter net loss widened to $38.7 million. It also partnered with Erasca for combination studies.
Key Points
- 1Stock jumps 52.15% week-on-week after Stifel buy rating and trial initiation
- 2Financials show 48.3% revenue growth and narrowed 2024 net loss to $101.59M
- 3Clinical development expands with Erasca collaboration and planned combo trials for pancreatic cancer
Scoring Rationale
Company-level financial updates and trial starts provide actionable investor insight, but limited scope and tangential relevance lower impact.
Sources
Public references used for this report.
Practice with real Health & Insurance data
90 SQL & Python problems · 15 industry datasets
Used by DS/ML engineers at top companies
250 free problems · No credit card
See all Health & Insurance problems